MX2016004678A - Composiciones para el tratamiento del cancer. - Google Patents

Composiciones para el tratamiento del cancer.

Info

Publication number
MX2016004678A
MX2016004678A MX2016004678A MX2016004678A MX2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating cancer
treatment
cancer
Prior art date
Application number
MX2016004678A
Other languages
English (en)
Inventor
A Toretsky Jeffrey
Uren Aykut
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of MX2016004678A publication Critical patent/MX2016004678A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Métodos y composiciones aquí proporcionadas se relacionan con el tratamiento del cáncer. En algunas modalidades, las composiciones titnen utilizad en el tratamiento de cánceres incluyendo glibastoma multiforme y cáncer de pulmón.
MX2016004678A 2013-10-24 2014-10-20 Composiciones para el tratamiento del cancer. MX2016004678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895308P 2013-10-24 2013-10-24
PCT/US2014/061418 WO2015061229A1 (en) 2013-10-24 2014-10-20 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
MX2016004678A true MX2016004678A (es) 2017-03-10

Family

ID=52993423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004678A MX2016004678A (es) 2013-10-24 2014-10-20 Composiciones para el tratamiento del cancer.

Country Status (11)

Country Link
US (2) US9511050B2 (es)
EP (1) EP3060207A4 (es)
JP (1) JP6389884B2 (es)
KR (1) KR20160065986A (es)
CN (1) CN105848654B (es)
AU (1) AU2014340398A1 (es)
CA (1) CA2927148A1 (es)
IL (1) IL245281A0 (es)
MX (1) MX2016004678A (es)
RU (1) RU2016114498A (es)
WO (1) WO2015061229A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
KR102037619B1 (ko) 2008-10-22 2019-10-28 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2011256380C1 (en) 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
CN107011242B (zh) 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
JP6389884B2 (ja) * 2013-10-24 2018-09-12 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ 癌を治療するための方法及び組成物
MX2017003589A (es) 2014-10-09 2018-08-15 Oncternal Therapeutics Inc Compuestos de indolinona y usos de los mismos.
EP3699181B1 (en) 2014-11-16 2023-03-01 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
KR102277538B1 (ko) * 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
SG11201803438XA (en) 2015-10-26 2018-05-30 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
ES2823190T3 (es) 2016-03-31 2021-05-06 Oncternal Therapeutics Inc Análogos de indolina y usos de los mismos
SG11201808559PA (en) 2016-04-04 2018-10-30 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
US10613088B2 (en) * 2016-06-12 2020-04-07 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
EP3490553A4 (en) 2016-07-29 2020-03-25 Oncternal Therapeutics, Inc. USE OF INDOLINON COMPOUNDS
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JP7356349B2 (ja) * 2017-02-28 2023-10-04 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 前立腺癌検出
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110845389A (zh) * 2019-10-17 2020-02-28 袁健 一种新型i型拓扑异构酶抑制剂
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
EP1135123B1 (en) * 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
CA2562151C (en) 2004-04-30 2016-09-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a c5-modified pyrimidine
WO2006117414A1 (es) 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Modelo animal no humano de sarcoma
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
CA2711003C (en) * 2006-12-29 2017-02-21 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
ES2434693T3 (es) 2007-04-20 2013-12-17 The Research Foundation For The State University Of New York Bencimidazoles y composiciones farmacéuticas de los mismos
TW201346030A (zh) 2012-04-02 2013-11-16 Gradalis Inc 依汶氏（ＥＷＩＮＧ’Ｓ）肉瘤雙功能ｓｈＲＮＡ設計
CN107011242B (zh) 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
JP6389884B2 (ja) * 2013-10-24 2018-09-12 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ 癌を治療するための方法及び組成物

Also Published As

Publication number Publication date
US20160263086A1 (en) 2016-09-15
CA2927148A1 (en) 2015-04-30
RU2016114498A (ru) 2017-11-29
US20170157089A1 (en) 2017-06-08
US9511050B2 (en) 2016-12-06
CN105848654A (zh) 2016-08-10
CN105848654B (zh) 2018-10-02
WO2015061229A1 (en) 2015-04-30
JP2016534084A (ja) 2016-11-04
KR20160065986A (ko) 2016-06-09
RU2016114498A3 (es) 2018-08-13
EP3060207A1 (en) 2016-08-31
IL245281A0 (en) 2016-06-30
EP3060207A4 (en) 2017-04-12
AU2014340398A1 (en) 2016-06-09
JP6389884B2 (ja) 2018-09-12

Similar Documents

Publication Publication Date Title
MX2016004678A (es) Composiciones para el tratamiento del cancer.
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2016002974A (es) Eteres de arilo y sus usos.
SG10201801433XA (en) Composition and vaccine for treating prostate cancer
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
PH12018502570A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
TW201611843A (en) Methods of treatment with arginine deiminase
GEP20197049B (en) Compositions and methods for treating surface wounds
IN2014DN09228A (es)
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PH12015502405A1 (en) Methods and compositions for wound healing
MX2015013021A (es) 5-bromo-indirrubinas.
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
MX369455B (es) Métodos mejorados para tratamiento de grano con ozono.